Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Liposarcoma × Immunoglobulin G × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 19 Carcinoma, Non-Small-Cell Lung 14 Ovarian Neoplasms 13 Fallopian Tube Neoplasms 11 Colorectal Neoplasms 10 Pancreatic Neoplasms 8 Triple Negative Breast Neoplasms 7 Melanoma 7 Carcinoma, Hepatocellular 7 Squamous Cell Carcinoma of Head and Neck 6 Breast Neoplasms 6 Urinary Bladder Neoplasms 5 Prostatic Neoplasms 5 Mycosis Fungoides 5 Lymphoma, T-Cell, Cutaneous 5 Carcinoma, Renal Cell 5 Neoplasm Metastasis 4 Sezary Syndrome 3 Sarcoma 3 Neoplasms 3 Myelodysplastic Syndromes 3 Multiple Myeloma 3 Lymphoma, T-Cell 3 Leukemia, Myeloid, Acute 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Endometrial Neoplasms 3 Carcinoma, Transitional Cell 3 Uterine Cervical Neoplasms 2 Urogenital Neoplasms 2 Urethral Neoplasms 2

Interventions

Radiotherapy 7 Doxorubicin 7 pazopanib 4 Trabectedin 4 Gemcitabine 4 ribociclib 3 palbociclib 3 eribulin 3 selinexor 2 pembrolizumab 2 liposomal doxorubicin 2 avelumab 2 Sunitinib 2 Radiation Dose Hypofractionation 2 Ifosfamide 2 Docetaxel 2 Cyclophosphamide 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 zimberelimab 1 temsirolimus 1 sotigalimab 1 sodium thiosulfate 1 sitravatinib 1 silmitasertib 1 sargramostim 1 romidepsin 1 regorafenib 1 plitidepsin 1 pegfilgrastim 1 olaparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04668300 2025-10-09

DOSa

M.D. Anderson Cancer Center

Phase 2 Active not recruiting

Hemangiosarcoma, Liposarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡